| The following article features coverage from the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Click here to read more of Oncology Nurse Advisor‘s conference coverage. |
The efficacy and safety of various antiemetic regimens for alleviating chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy were assessed in a study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS 2017).
Oral combinations of netupitant and palonosetron (NEPA) may be a better choice than conventional regimens, reported the researchers.
Continue Reading
For this study, the researchers reviewed 24 randomized control trials encompassing 12,104 participants and 12 different antiemetic regimens. They found that the following 3 regimes: palonosetron (PAL) 0.75 mg plus dexamethasone (Dex), aprepitant (APR) plus a serotonin-3 receptor antagonist (5HT3) and Dex, and APR + PAL 0.25 mg or 0.50 mg and Dex were more promising than existing reference regimens. In addition, oral combinations of netupitant and palonosetron (NEPA) were found more effective than conventional regimens.
However, olanzapine (OLZ) containing regimens were the most effective at curbing CINV. OLZ-containing regimens could be the best choice; however, the researchers suggest that further clinical studies are needed.
Reference
Yokoe T, Hayashida T, Nagayama A, et al. Comparative effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Poster Presentation at: 2017 San Antonio Breast Cancer Symposium; December 6-9, 2017; San Antonio, TX. Abstract P3-14-11.
